Home / Business and Economy / Ahold Delhaize Pays $40M Over Prescription Pricing
Ahold Delhaize Pays $40M Over Prescription Pricing
18 Jun
Summary
- Supermarket chain operator agrees to $40 million settlement.
- Allegations involve inflated prescription drug pricing data.
- Settlement impacts federal healthcare programs like Medicare Part D.
Ahold Delhaize USA has agreed to pay $40 million to resolve allegations of submitting inflated prescription drug pricing data to federal health care programs. The company operates well-known grocery chains including Giant, Stop & Shop, and Food Lion.
Federal authorities alleged that Ahold Delhaize failed to report discounted prescription prices as its 'usual and customary' rates when billing programs like Medicare Part D, Medicaid, and Tricare. This practice, according to the government, led these programs to reimburse pharmacies at higher amounts.
The settlement specifically pertains to pharmacy billing practices and does not affect consumer pricing at the grocery stores. The Justice Department emphasized that accurate pricing information is crucial for federal healthcare programs' payment formulas.
The allegations were initially brought forward by a whistleblower pharmacist who worked for the company. This case underscores the impact of prescription pricing disclosures on taxpayer-funded healthcare spending.
